Received May 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 47N3Y | — |
Shingrix - Administration of only the adjuvant component; patient received only the adjuvant portion of Shingrix without the lyophilized component; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a 61-year-old female patient who received Herpes zoster (Shingrix) (batch number 47N3Y, expiry date 30-MAR-2027) for prophylaxis. On 21-MAY-2025, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: Shingrix - Administration of only the adjuvant component) and inappropriate dose of vaccine administered (Verbatim: patient received only the adjuvant portion of Shingrix without the lyophilized component). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 21-MAY-2025 A pharmacist reported that a patient received only the adjuvant portion of Shingrix without the lyophilized component. The pharmacist asked if they could reconstitute the powder with a different diluent such as sterile water and then administered this solution to the patient. The patient received only adjuvant of Shingrix, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.